Valeant Receives Antitrust Clearance for Obagi Purchase

The waiting period for Valeant Pharmaceuticals (NYSE: VRX  ) acquisition of Obagi Medical  Products  (UNKNOWN: OMPI.DL  ) under the Hart-Scott-Rodino Antitrust Improvements Act, or HSR, expired on April 19, the company announced today, allowing the transaction to move to the next phase. 

Valeant offered to buy Obagi for $19.75 a share on March 20. A subsequent bid by Merz Pharma for $22 a share led Valeant to raise its offer earlier this month to $24 a share, or $417 million.

The HSR requires merging companies to file detailed reports with the FTC and the Justice Department to see whether the combination violates antitrust laws. There is a 30-day waiting period (15 days for all-cash transactions) before the merger can be completed. The companies can request the waiting period be terminated early, which will be granted if both antitrust agencies complete their reviews and determine that no enforcement action is necessary.

The completion of the tender offer is also conditioned on approval of the Antimonopoly Committee of Ukraine for purposes of compliance with applicable Ukrainian antimonopoly law. Although there can be no guarantee or assurance, Valeant believes it is possible that the parties may receive approval from the committee in the near future. 

Valeant also requires the tender of a majority of the outstanding shares of common stock of Obagi, which it expects to complete promptly after the committee's approval.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2377928, ~/Articles/ArticleHandler.aspx, 8/29/2014 8:11:23 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement